Characteristics of lipid metabolism disorders in patients with coronavirus infection-COVID-19 with chronic hepatitis C

The aim of the study was to assess individual indicators of lipid metabolism in patients with novel coronavirus infection with chronic hepatitis C (CHC) depending on the severity of COVID-19 and liver fibrosis stage.Object and methods. A comparative analysis of the results of laboratory examination of patients of the following groups was carried out: group 1 (n = 147) - patients with COVID-19 and CHC, group 2 (n = 81) - patients with COVID-19, group 3 control (n = 94) patients with CHC without COVID-19. In turn, the patients of the first two groups were divided into subgroups according to the severity of the COVID-19: with moderate (A) and severe course (B). According to the liver fibrosis stage, patients with COVID-19 with CHC were divided into 3 subgroups: F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis). In blood serum, lipid profile parameters (total cholesterol (TC), high-density lipoprotein cholesterol (CHDL), low-density lipoprotein cholesterol (CLDL), triglycerides (TG), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B)) were evaluated. All parameters were assessed in the acute period, according to the severity of COVID-19 and the liver fibrosis stage.Results. In 100% of patients with COVID-19 and CHC, a decrease in Apo A1 and an increase in Apo B, the ratio of Apo B/Apo A1 were detected, regardless the severity of disease. In patients with severe COVID-19 with CHC, changes in the lipid spectrum were recorded: an increase in TG, Apo AI, Apo B, Apo B/Apo A1 ratio, and a decrease in CHDL, CLDL, Apo A1. In patients with COVID19 and severe liver fibrosis (CHC), a decrease in LDLC, Apo A1 and increase in CLDL, Apo B, ratio Apo B/Apo A1 was observed.